Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Alette M. Wessels"'
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction The Integrated Alzheimer's Disease Rating Scale (iADRS) has been used to detect differences in disease progression in early Alzheimer's disease (AD). The objectives of this study were to enhance understanding of iADRS point chan
Externí odkaz:
https://doaj.org/article/f1475d039f7948df85c74296ac37d6f8
Autor:
Jennifer A. Zimmer, Sergey Shcherbinin, Michael D. Devous Sr., Sonja M. Bragg, Katherine J. Selzler, Alette M. Wessels, Craig Shering, Jamie Mullen, John Landry, Scott W. Andersen, AnnCatherine M. Downing, Adam S. Fleisher, Diana Otero Svaldi, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic pla
Externí odkaz:
https://doaj.org/article/b11b2d19d9184e3eb390acfbb6efc91b
Autor:
Dorene M. Rentz, Alette M. Wessels, Ananth V. Annapragada, Anna‐Karin Berger, Chris J. Edgar, Michael Gold, David S. Miller, Christopher Randolph, J. Michael Ryan, Glen Wunderlich, Megan Canniere Zoschg, Dominic Trépel, David S. Knopman, Adam M. Staffaroni, Lisa J. Bain, Maria C. Carrillo, Christopher J. Weber
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Rese
Externí odkaz:
https://doaj.org/article/3861e88838da4e6ebedaf1d05ef042a6
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES.
An Alzheimer's disease (AD) dementia disease progression model was developed based on the integrated Alzheimer's Disease Rating Scale (iADRS).Data from 3483 placebo participants in six AD trials were used to develop the disease progression model with
Autor:
Cynthia Duggan Evans, Daniel Skovronsky, Paul A. Ardayfio, JonDavid Sparks, Mark A Mintun, Sergey Shcherbinin, Scott W. Andersen, Liana G. Apostolova, Miroslaw Brys, John R. Sims, Alette M. Wessels, Albert C. Lo, Stephen Salloway
Publikováno v:
New England Journal of Medicine. 384:1691-1704
Background A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for t...
Autor:
Alette M. Wessels, Chris J. Edgar, Eric Siemers, John Harrison, Pradeep J. Nathan, Paul Maruff
Publikováno v:
Drug Discovery Today. 26:1330-1336
Go/No-Go decision making in early phase clinical trials is challenging for drug developers working in Alzheimer's disease. Recent negative trial results have been attributed to a lack of efficacy and important safety concerns. Furthermore, demonstrat
Autor:
Alette M. Wessels, Ellen B. Dennehy, Sherie A. Dowsett, Samuel P. Dickson, Suzanne B. Hendrix
Publikováno v:
Neurology: Clinical Practice. 13:e200127
Purpose of ReviewTo provide relevant background of the Integrated Alzheimer's Disease Rating Scale (iADRS), with examples, to assist the reader with the interpretation of iADRS findings from the TRAILBLAZER-ALZ study.Recent FindingsThe iADRS is an in
Autor:
Roy Yaari, Chung-Kai Sun, Kathryn V. Papp, Karen C. Holdridge, Reisa A. Sperling, Paul Maruff, Dorene M. Rentz, Michael A. Yassa, Adrian Schembri, Rema Raman, Michael C. Donohue, Paul S. Aisen, Alette M. Wessels, Craig E.L. Stark
Publikováno v:
The journal of prevention of Alzheimer's disease
Background: Computerized cognitive assessments may improve Alzheimer’s disease (AD) secondary prevention trial efficiency and accuracy. However, they require validation against standard outcomes and relevant biomarkers. Objective: To assess the fea
Publikováno v:
The New England journal of medicine. 385(7)
Autor:
Anna-Karin Berger, David Miller, Chris J. Edgar, Christopher Randolph, Ananth Annapragada, Michael Gold, Lisa J. Bain, Christopher J. Weber, Dominic Trépel, David S. Knopman, Glen Wunderlich, J. Michael Ryan, Alette M. Wessels, Dorene M. Rentz, Maria C. Carrillo, Megan Canniere Zoschg, Adam M. Staffaroni
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roun